Get Support

Learn Mode

CRSP - CRISPR Therapeutics AG

195

$51.76

$2.06 (4.145%)

At market close

$51.51

-$0.25 (-0.492%)

Pre Market 4/9/26, 11:50 AM

2.36/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

CRSP

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$4.97B

Industry

Biotechnology

EPS (TTM)

-$6.10

P/E (TTM)

0.00

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

1,415.44

P/B

2.59

Diluted Shares

95.33M

Ex-Dividend

--

Next Earnings

05-04

Forward P/E

0.00

Payout Ratio

--

P/FCF (TTM)

0.00

FCF Yield

--

Earnings Yield

-11.71%

52 Week Range

Score Card

Explore Scores Tab

2.36

Bad

CRISPR Therapeutics AG has negative free cash flow of -370.93M, which means it is currently losing money. Also, it has negative operating cash flow of -345.01M, which means its not generating any profits on its operations.

Valuation Model

Key Score

2.00

Bad

Management

3.00

Average

Growth

1.00

Very Bad

Profitability

3.00

Average

Fin. Health

5.00

Very Good

Dividends

--

--

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form PRE 14A

Unknown Form Type

Filed on 2026-04-02 16:23:21

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 17:38:39

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 17:37:54

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 17:37:11

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 17:36:41

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-17 17:37:40

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-17 17:37:03

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-17 17:35:54

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-17 17:35:20

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-16 16:06:45

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 17:35:06

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 17:35:04

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$305.55

490.3%

Avg:

$83.47

61.3%

Low:

$33.33

-35.6%

(% change is relative to the current stock price: $51.76)

Analyst Recommendations

Go to Analyst Tab

3.86

Good

26%

Strong Buy (9)

37%

Buy (13)

34%

Hold (12)

3%

Sell (1)

0%

Strong Sell (0)

About

Website
https://crisprtx.com/
Address
Baarerstrasse 14, Zug ZUG, CH
SEC Reports
https://sec.gov/edgar/browse/?CIK=1674416

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

IPO Date

2016-10-19

Industry

Biotechnology

Total Employees

393

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences